Verde G, Oppizzi G, Chiodini P G, Dallabonzana D, Luccarelli G, Liuzzi A
J Endocrinol Invest. 1985 Apr;8(2):113-5. doi: 10.1007/BF03350660.
The effect of chronic bromocriptine administration (7.5-20 mg/day for 1-32 months) on the size of "nonsecreting" pituitary adenomas (NPA) was studied in 20 patients. Brain computed tomography showed a marked reduction of the adenoma in one patient after 1 month of treatment (7.5 mg/day); further scans taken 2 and 15 months later, under the same bromocriptine dose, did not show any other variations in the tumoral mass. In the remaining 19 patients, no changes in tumor size were documented by CT during the treatment. Four patients had a worsening of visual fields during bromocriptine administration and they were referred for neurosurgery. In conclusion, bromocriptine was ineffective in reducing tumor size in all but one patient with NPA and, in some cases, it did not prevent tumor growth as is suggested by the worsening of visual fields. Thus, bromocriptine treatment, at least at the doses capable of shrinking macroprolactinomas, seems to be of limited value in patients with NPA.
对20例患者研究了长期服用溴隐亭（7.5 - 20毫克/天，持续1 - 32个月）对“无分泌功能”垂体腺瘤（NPA）大小的影响。脑部计算机断层扫描显示，1例患者在治疗1个月（7.5毫克/天）后腺瘤明显缩小；在相同溴隐亭剂量下，2个月和15个月后进行的进一步扫描未显示肿瘤块有任何其他变化。在其余19例患者中，治疗期间CT未记录到肿瘤大小变化。4例患者在服用溴隐亭期间视野恶化，被转诊进行神经外科手术。总之，除1例NPA患者外，溴隐亭对缩小肿瘤大小无效，而且在某些情况下，如视野恶化所示，它并不能阻止肿瘤生长。因此，至少在能够缩小大泌乳素瘤的剂量下，溴隐亭治疗对NPA患者似乎价值有限。
